Despite the success of vaccines in reducing the morbidity and mortality associated with infectious diseases, many infectious diseases, both newly emerging and well known, lack vaccines. The global capability for beginning-to-end vaccine development has become limited, primarily owing to a scarcity of human capital necessary to guide the development of novel vaccines from the laboratory to the marketplace. Here, we identify and discuss the gaps in human capital necessary for robust vaccine development and make recommendations to begin to address these deficiencies.
Introduction
The development and use of vaccines to prevent infectious diseases has been an extraordinary public health success yielding substantial reductions in worldwide morbidity and mortality over the past half-century. However, many infectious diseases remain for which vaccines are not available, both for infections that have been recognized for many years and for those that are newly emerging on a large scale owing to increasing global interconnectivity. Unfortunately, the world's ability to develop the badly needed new vaccines has become overly limited, with an attendant increase in concern within the public health community. Of the various factors that conspire to drive this concern, a particularly critical one is an ongoing decline in experienced human capital needed to guide the process of vaccine development from the research laboratory to a safe and effective licensed product. To begin addressing this concern, a meeting was held with vaccine leaders from industry, government, academia, and relevant private organizations under the auspices of the New York Academy of Sciences. This report provides a synthesis of the discussions and conclusions that followed from the deliberations of the meeting participants, emphasizing the importance of experienced human engagement in vaccine development and concerns over evolving deficiencies in required human capital. Recommendations were considered and are presented here that hopefully can begin to address the identified deficiencies.
Background

Current fragile state of vaccine development
Over the past half-century, vaccine development has been primarily performed within large pharmaceutical organizations with the capital and expertise needed to manage and produce complex biological products. Vaccine development includes basic science and academic laboratory discovery followed by translation to preclinical product development, regulatory oversight, clinical trials, and manufacturing. Our focus here is on these later stages of beginning-to-end development. The number of large integrated organizations that can implement beginning-to-end vaccine development has decreased over the past several decades for a variety of reasons. These include the consolidation of vaccine companies through mergers and acquisitions, the requirement for large capital investments that are considered out of proportion to the market potential, pricing pressures, and high clinical development costs to satisfy regulatory requirements. 1 In 1967, there were 26 companies with vaccine licenses issued by the U.S. Food and Drug Administration (FDA) 2 ( Fig. 1 ). These 26 companies have been reduced to 15, with only eight holding FDA licenses for more than one vaccine. 3 Of those companies, only six hold licenses for vaccines against more than one pathogen type. 3 As recently as 2015, most of Novartis's vaccines were acquired by GlaxoSmithKline, 4 and the remaining Novartis influenza franchise was consolidated with that of CSL's, 5 reflecting the continuing consolidation within the industry. Therefore, there are currently only four large multinational manufacturing institutions that focus on vaccine development (GlaxoSmithKline, Merck, Pfizer, and Sanofi-Pasteur) 6 and that have the capability to conduct comprehensive, end-to-end vaccine research, development, and manufacturing. While the number and capacity of vaccine manufacturers in developing countries continue to increase (e.g., with companies like Serum Institute of India, which is engaged in some beginning-to-end vaccine development), the focus of most of these companies largely remains the development and manufacturing of existing vaccines using adaptation of existing technologies and not the full spectrum of end-to-end vaccine development activities.
On the other hand, recent years have witnessed a noted increase in the number of early research organizations engaging in vaccine research, including academic and government laboratories and biotechnology companies. This has resulted in a commensurate increase in early vaccine candidates entering the pipeline, primarily in preclinical phase and in early clinical trials. 7 This is potentially good news for progress toward developing new and improved vaccines, particularly for those focused on emerging diseases and/or diseases whose primary impact is in low-income countries. However, the beginningto-end vaccine-development environment (with the required infrastructure and capital) needed to carry these potential vaccine products forward is limited.
One of the effects of this increasing limitation in the later-stage vaccine-development environment is a decline in the number of sufficiently trained personnel with vaccine development expertise available to populate industry, governments, product development partnerships (PDPs), and emerging/lowerresource country vaccine manufacturers to direct future vaccine development and production. This limitation, along with the aging of the population of seasoned vaccinologists, is contributing to a situation in which there is a shortage of trained individuals with robust, hands-on experience in the end-to-end vaccine-development process to permit the successful development of new vaccines. 8 There exists an understandable but unfortunate lack of commercial interest within the large, integrated vaccine-development institutions to develop vaccines that, while relatively limited in commercial potential, are nonetheless essential for control of infections with significant worldwide health importance. Currently, the economics of supporting the development of such vaccines, given the required infrastructure investment and the multi-year commitment for development (which can be a decade or more), are not considered viable. The global vaccine development fund recently recommended by Plotkin, Mahmoud, and Farrar represents a potentially important step to improve the availability of dedicated and prioritized vaccine funding. 6 However, such funding will be insufficient to achieve the desired goals without substantial improvement in the operational relationships among industry, academia, government, and nongovernmental organizations and with significant emphasis on increasing the number of trained and experienced personnel capable of driving and managing effective vaccinedevelopment efforts.
Description of the nature of the project to address the current state The current project began under the auspices of the New York Academy of Sciences in 2013 as a general evaluation of gaps in vaccine development. Key vaccine stakeholders from industry, government, academia, and private organizations were individually interviewed by New York Academy of Sciences personnel about their views on vaccine development in both developed and emerging countries. Interviewers assessed perspectives on the most important challenges to novel vaccine development, along with possible solutions. Some of the specific items surveyed included challenges with resources (fiscal, human, physical), regulatory policy, market guarantees, prioritization, engagement of industry and government, technology, and the role of PDPs and public-private partnerships (PPPs). Multiple challenges for vaccine development were raised by those interviewed, including the lack of adequate funding and financial reward, varying regulatory frameworks, regional differences in disease burden, lack of a global priority list, and difficulties identifying novel vaccine candidates. While many issues were identified, there was a general consensus that a key barrier hindering global vaccine development is the lack of trained and knowledgeable vaccine development-experienced human capital.
On the basis of this general consensus, we decided to focus further discussions on the current state of human capital in vaccine development. A second series of interviews was held with the stakeholders in May 2014 to assess views on (1) the specific human capital expertise needed, (2) the stage of the vaccine-development pipeline where humancapital gaps are most prevalent, (3) the reasons for and consequences of these gaps, and (4) potential solutions. A subsequent workshop was held in April 2015 with stakeholders to further probe interview responses and to gain consensus on identified targets for actions, proposed solutions, and next steps for implementation, as presented in the remainder of this report.
The primary actionable targets for gaps in human capital in vaccine development were identified to be in the early translational development segment of the vaccine development process, including process development, analytical and formulation development, translational clinical studies, and regulatory science and strategy. While several solutions were discussed, a specific approach was initially recommended to facilitate further discussion and action. The proposal recommended establishing a virtual or free-standing vaccine research and development (R&D) institute focused on the early translational development of selected vaccines that are of obvious global public health importance but are not of current commercial interest. This proposed solution simultaneously addresses two issues currently affecting vaccine development: the future lack of appropriately trained and experienced personnel to support specialized aspects of vaccine development, particularly the early translational development process; and the limited number of fully integrated vaccine R&D institutions engaged in development of vaccines of limited commercial interest but global health importance. The following sections describe the specific human capital gaps in greater detail and provide additional specifics of a virtual or free-standing institute and other recommendations for remediation.
Discussion of human capital gaps in key vaccine-development functions
From basic research through development to manufacturing A lack of comprehensive knowledge about the path from discovery to development and manufacturing among those performing basic research can contribute to a poor choice of early vaccine targets that can be developed. An understanding of presentation, scalability, accepted immunization schedules, and regulatory implications and barriers in a global setting are needed to minimize the risks of pursuing vaccine candidates that will face stiff and potentially insurmountable barriers to development of viable, effective, and licensed vaccines.
Because vaccines are complex biological products that range from recombinant subunit antigens to whole attenuated organisms, their manufacturing processes and associated control analytics are technically challenging. The objective is to ensure that a given vaccine is safe, effective, of the highest quality, and stable. The development of vaccines from targets discovered in research laboratories to final products involves substantial and critical efforts in formulation, process, and analytical development activities. The integration of clinical development from phase I through phase III trials with the development of the processes, formulation, and analytical test methods is critical for overall vaccine-development success. These activities require highly trained and knowledgeable individuals to perform these functions in a coordinated, cross-functional, and well-organized manner. A recent report describing the lessons learned from a successful process scale-up and production of an investigational vaccine targeting the Ebola virus emphasized the importance of increased knowledge and having "a deep understanding of vaccine manufacturing technology--preferably platform technologies" in order to achieve rapid scale-up and ultimately to be able to develop and supply the vaccines to those who need them most. 9 Unfortunately, there is a lack of trained individuals with specific vaccine expertise available in the functional areas of development (formulation, process, analytical, and clinical) to translate research targets to full-scale manufactured products, and the prospects to fill these gaps are poor. Currently, these experts are primarily concentrated in the large-scale commercial entities, as this is the setting that has historically carried out these activities. As noted by the National Vaccine Advisory Committee, "Expertise in process development resides almost exclusively in the large companies; there is no other resource for such development." 10 When looking across the spectrum of vaccine-development activities, it is large integrated companies that have made the most contributions in process and clinical development, manufacturing, and postlicensure studies. 10 With the decline in the number of commercial, large-scale vaccine-development companies (largely because of consolidation) follows a reduction of experienced and trained vaccine professionals in these settings, as well as a limited ability to train new, young scientists. In addition, small biotechnology companies and PPPs face challenges in attracting and recruiting a complete range of experienced vaccinedevelopment personnel to permit a fully integrated beginning-to-end vaccine-development capability. The expertise and skills required in vaccine development are not readily obtained through current academic disciplines. There are limited training and experiential opportunities for individuals to learn vaccine formulation, development, and production, and mentorships by experienced personnel, integral to career development, are also in short supply.
To best support vaccine development and access in low-or middle-resource countries, expertise is best placed in these regions to support and promote local vaccine manufacturing. While novel vaccine development does not typically occur in low-resource countries, there is an increasing trend for manufacturing to be set up in these regions. Experience working in a large pharmaceutical company has been deemed important for learning more about the corporate culture that makes a successful R&D company and to obtain the necessary handson training required for vaccine development. However, low-resource country residents who have made the investment to work and obtain hands-on training in a large-scale vaccine or pharmaceutical company often do not return to their home countries. For those who remain in the low-resource country, there are limited training opportunities.
In addition to development activities, manufacturing quality management is one of the most conspicuous human capital gaps in developing/ emerging countries, most often due to a lack of quality senior manufacturing personnel with the required high level of expertise and experience in manufacturing processes.
Regulatory science and strategy A second major area in which gaps in human capital were noted is regulatory science and strategy. This expertise involves the use of scientific methods to improve the development, review, and oversight of new vaccines that require regulatory approval; it requires expertise in many areas that are not included in academic training, including clinical trial design, product quality evaluation, data mining and management, quantitative safety assessment, and preclinical toxicology. The lack of sufficiently trained and available individuals who understand global regulatory requirements and regulatory science has the potential to affect both vaccine development (i.e., sponsor) and approval (i.e., regulatory agency) and can impede efficient vaccine development and licensure of new vaccines. Since there are a variety of regulatory requirements across the globe, regulators in different countries and agencies often do not understand each other's challenges and processes, which hinders product development. In addition, the lack of regulators who have sound knowledge of the overall vaccine development process can impede or delay vaccine development (e.g., they may not understand regulatory implications of changes in such things as vaccine components or manufacturing processes). The same holds true for development scientists, who may make changes in processes without understanding the regulatory impact of the changes.
Vaccine developers and manufacturers are the primary employers of individuals with regulatory science expertise in the manufacture and control of biologicals, the target diseases, animal modeling, and assessment of clinical evidence. 11 Causes of the human-capital gap in this area include the consolidation of these large-scale vaccine companies, as well as, according to one advisor, an apparent decline of mentorship opportunities and relationships at the FDA and of time for more senior staff to mentor trainees. As with training in vaccine translational development, most training in regulatory science is obtained on the job, but there currently are limited opportunities for beginning-to-end vaccinedevelopment exposure to serve as fertile training grounds for regulatory scientists. There are some opportunities available for formal regulatory science training, and the FDA has been working to improve these opportunities. One such effort is the establishment of the Centers of Excellence in Regulatory Science and Innovation, which includes collaborations between the FDA and academic partners (University of Maryland, Georgetown University, University of California at San Francisco-Stanford, Yale-Mayo Clinic, and Johns Hopkins University) focused on the conduct of regulatory science research for key scientific challenges and on the training of the next generation of regulatory scientists. 12 Nonetheless, many regulatory agencies in resource-poor countries have a limited number of experienced regulators, and these are often responsible for many different types of regulations. It is therefore very difficult for regulators to have a robust knowledge base regarding regulatory considerations specifically pertaining to vaccine development and licensure. In addition, in many of these countries, the regulations for vaccine development and manufacturing may be incomplete or insufficient. As part of the Centers of Excellence initiative described above, the FDA has been leading an effort to train international regulators so that they can establish Centers of Excellence in their respective regions through which they can continue to train future regulators. 13 It is too soon to judge the impact of this program.
Overall recommendations
To address the key challenge of a lack of adequately trained human capital to develop vaccines, and in particular to facilitate the development of vaccines of global health importance, the workshop participants proposed a series of recommendations complementary to those of Plotkin, Mahmoud, and Farrar 6 and focused on providing an enabling environment for the proposed Global Vaccine Fund or other similar future novel sources of funding.
Establish a vaccine R&D institute (either virtual or freestanding)
The institute should be focused on the early translational development of selected vaccines that are of clear global public health importance but are not of current commercial interest.
Infrastructure and characteristics.
Unlike similar past concepts, the proposed institute would be a consortium comprising facility and personnel currently affiliated with multiple multinational and national full-scale vaccine research, development, and manufacturing entities, all of which are involved in vaccine R&D and thus possess the required capabilities. A university-based component would be included to provide formal academic support for associated training programs (see below) and public health expertise. As an example, a vaccine institute could be created at a university in the Northeast United States, where most of the vaccine industry and government regulatory infrastructures are located. Faculty could include people retired from industry, with adjunct faculty from vaccine companies, the National Institutes of Health Vaccine Research Center, and established university centers for vaccine development. Financial support could come from industry, including industry in low-and middle-income countries. The curriculum and training would include didactic instruction, but also practical assignments to institutions engaged in early development of vaccine products, doing clinical trials, and making good manufacturing practice lots of vaccines.
Masters or higher-level degrees would be awarded to graduates on the basis of curricula and disciplines studied. The institute's strategy, focus, and priority for vaccine-development targets would be guided by a board comprising members of the participating/funding organizations, while coordinated operations would be managed by a dedicated operational/management group.
While the contributing multinational and national commercial entities may have expertise in end-to-end R&D capabilities, the proposed organization would focus on the areas where the human capital gaps are greatest, specifically vaccine earlydevelopment translational work, including process development, formulation and analytical development, translational clinical studies (including proof-of-concept efficacy), and regulatory strategy/support. As a pilot, the institute could initially support one or two programs to be selected by the strategic board using agreed-upon criteria. Projects to be engaged should have sufficient existing research basis to permit entry into the early development process. This latter process, conducted within the institute, would drive the acquisition of clinical, regulatory, and manufacturing data needed to make the program sufficiently attractive to support its continued development by external private or public entities.
Education and training. The institute would be staffed with appropriately experienced personnel from the contributing organizations, in addition to the contribution of development facilities and materials. However, a reasonable proportion of the institute's activities would be staffed by personnel in training, including assignments to development, clinical research, and/or regulatory science functions. The latter could include time-limited practical, hands-on training opportunities, as well as more formal degree-focused training programs that could be implemented under the auspices of a collaborating university. Master's and doctoral degree programs and postdoctoral fellowships in vaccinology could be awarded by the institute. Academic institutions with some level of existing training in vaccine development, such as the Center for Vaccine Development at the University of Maryland School of Medicine, 14 or with multiple schools and disciplines relevant to vaccine development, such as public health, medicine, and engineering, would be excellent places to begin to explore such a collaboration. Efforts should be made to attract training candidates from lower-to middle-income countries, particularly in the areas of clinical research and regulatory science. Various incentives/options could be proposed to help ensure that those trained would feed back into areas where human capital gaps in vaccine development exist.
Funding and benefits to contributors. The funding would be provided in kind by the participating commercial pharmaceutical organizations, with added financial support and contributions from private foundations and government. The primary benefits to the contributing commercial organizations would be access to a developing pool of new and young talent and access to the intellectual benefits of a unique vaccine-development environment. The contributing funders would benefit from the increase in available talent and from sourcing some of that new talent to developing country vaccine manufacturers, as well as from the advancement of vaccines of global health interest. The trainees would benefit by having an institute within which they could receive both formal academic training and hands-on practical training working on important vaccine projects for improving global health. In addition, it may be possible to structure the institute in a way (such as a foundation) that could provide tax benefits to donors.
Increase advocacy to attract more top scientific talent to the field of vaccinology
Vaccines have had a significant impact on global public health, and the ability for young scientists to be involved in such an impactful field should attract those who want to make a difference. However, more focused efforts are needed to increase awareness of the importance of vaccines and vaccine discovery in relation to other drug products, to tell the vaccine development story, to create a general understanding of the history of this field, and to highlight the need for further vaccine development in the future for both emerging and currently prevalent infectious diseases.
In order to spur interest in vaccine development in young scientists, an increase in advocacy efforts targeting this population of scientists would be beneficial. Increasing the number of articles in premier scientific publications and other publications that speak to the scientific challenges of vaccine development, the positive impact of vaccines on public health, the lack of vaccine expertise currently available for certain aspects of vaccine development, and the exciting new developments and technologies in vaccinology would also stimulate interest in young scientists looking for important and challenging fields of scientific study for which there are substantial resource needs.
Develop disease-specific consortia/networks that connect organizations and people from all parts of the vaccine development pipeline
The different components of the vaccinedevelopment pipeline are often cottage industries, working in silos; the development of a product in a laboratory is more likely to succeed when basic researchers communicate with translational scientists along the way. The increasing number of PDPs focused on disease-specific targets is a step in the right direction for early collaboration to improve the chances of success. However, even greater levels of collaboration and communication across organizations and people focused on specific diseases will not only increase the knowledge flow to scientists and across functional lines from basic research to translational development for informal training purposes, but should also improve the likelihood of success.
Create more opportunities for scientific dialogue and collaboration among industry, academics, and regulators through conferences and working groups A limited number of conferences and task forces currently bring together academia, industry, and regulators, but it was acknowledged that these are not frequent enough and typically only involve a few regulators. Expansion of appropriate educational settings will provide opportunities for new and junior colleagues to learn and to develop their expertise in regulatory science as well as other areas of vaccine development.
Raise awareness of the root cause of the decline in sustainability of the vaccine R&D sector and of potential solutions
To a large extent, the current situation reflects a belief in the declining commercial viability of vaccine R&D and production. Open discussion and awareness of this issue are needed, along with a comprehensive discussion of viable solutions, some of which have been discussed here.
Next steps
Participants (authors and stakeholders) interviewed for this project believe that the above-mentioned proposals will help mitigate gaps in human capital for vaccine development as well as promote the development of important vaccines. The next steps needed to support the further development and implementation of these proposals are as follows.
r Assemble a group of advisors from key stakeholder groups (e.g., government, industry, academia, and private organizations), including experts in vaccine research, translational development, clinical research, regulatory science, human resources, and education and training from the most relevant organizations.
r Agree to a common mission, set of goals, and prioritized agenda. Determine the governance and operational structure to drive and make decisions on the implementation of the proposals.
r Identify the characteristics of an ideal training program in vaccinology that combines both academic coursework and practical work experience. Investigate the strengths and weaknesses of existing vaccine-development academic and other training programs.
r Determine the resources that will be required and the institutions and organizations that can support these proposals in terms of financial and human resources and facilities. Large, integrated multinational organizations that have end-to-end development capabilities and expertise will be needed to donate facilities and experienced personnel. Financial resources may also be provided by private foundations that are currently providing significant financial support to vaccine development and access for developing countries, from government agencies involved in vaccine R&D, or from the proposed Global Vaccine Fund. 6 
Conclusions and call to action
A critical need to enable improved vaccine development was identified following interviews and discussions with multiple vaccine leaders across government, academia, industry, and nongovernmental organizations under the auspices of the New York Academy of Sciences. There is a growing deficit of trained vaccinologists who understand vaccine development from beginning to end and who are best placed to guide the development of new and novel vaccines from research to final products, particularly in the specific areas of translational development (formulation, process, analytical, clinical and regulatory sciences).
While there are a number of recommendations proposed in this report, a primary one involves the establishment of an institute that will focus on early translational development of vaccines that are of obvious public health importance but not necessarily of commercial interest. The institute will have access to individuals with experience in successfully advancing vaccine candidates through all stages of development, regulatory review, licensure, and production, and will focus on developing important vaccine targets by capitalizing on this expertise, establishing vaccine priorities, using donations (e.g., facilities, experienced staff, financial) from contributing organizations, and using vaccinologists-in-training engaged in formal academic programs. The proposal targets two important problems in vaccine development: (1) the future lack of appropriately trained and experienced personnel to support specialized aspects of vaccine development, particularly the early translational development process; and (2) the limited number of fully integrated vaccine R&D institutions engaged in the development of vaccines of limited commercial interest but of global health importance.
The next steps in moving this proposal forward would be to assemble an advisory committee composed of key stakeholders in vaccine development from industry, government, academia, and private foundations; to agree to the goals, structure, and governance for this institute; to identify the ideal training program for future vaccinologists encompassing both formal and hands-on practical components; and, most importantly but most challengingly, to obtain agreement on the degree of contributions available from each stakeholder. These steps will enable actions that will hopefully sustain the world's ability to develop vaccines critical for global human health for many years into the future.
